PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 7:04 AM ET

Sponsor Check › Person

PH
No photo found yet (own website and image search run after this page is viewed)

Patrick Heron

Named as an officer, director or promoter on SEC Form D filings · CA, NJ, RI, WA, OH, CO, MA, Ireland (as filed: L2), PA, IN · Apr 24, 2009 → Jun 30, 2026

34deals (issuers)
$4.99Breported sold
977investors
71Form D filings
2009–2026years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 3:01 AM ET · SEC enforcement last checked: Oct 24, 2026, 12:33 AM ET

The short version

Patrick Heron is listed as an executive officer, director, and promoter on 71 SEC Form D filings by 34 issuers between Apr 2009 and Jun 2026. Largest by amount reported sold: Frazier Life Sciences XI, L.P. (Menlo Park, CA — pooled investment fund — 2022; $960M reported sold to 98 investors), Frazier Healthcare Growth Buyout Fund IX, L.P. (Seattle, WA — pooled investment fund — 2017–2018; $775.7M reported sold to 138 investors), Frazier Healthcare Growth Buyout Fund VIII, L.P. (Seattle, WA — pooled investment fund — 2015–2016; $519.6M reported sold to 67 investors), Frazier Life Sciences Public Fund, L.P. (Palo Alto, CA — pooled investment fund — 2026; $475.7M reported sold to 142 investors), Frazier Life Sciences IX, L.P. (Seattle, WA — pooled investment fund — 2017; $418.9M reported sold to 55 investors) and 29 more (all listed below).

What this means That is a lot of deals — 34 separate companies raised money with this person listed as executive officer, director, and promoter, over about 17 years. Across those companies the filings report $4.99B sold in total.

Listed alongside Nathan Every (17 shared filings), James Topper (16 shared filings), Alan Frazier (12 shared filings), Nader Naini (12 shared filings), BRIAN MORFITT (10 shared filings) and 187 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Patrick. Each name links to their own page.

The issuers belong to 3 sponsor groups: Frazier Healthcare (26 issuers, $2.74B reported sold, 2012–2026), Iterum Therapeutics (2 issuers, $54.4M reported sold, 2015–2020) and Trius (2 issuers, $270.2M reported sold, 2009–2024).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 4 bankruptcy cases matching the name listed in Key records below.

What this means 4 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared the newest 50 of 71 public filings for Patrick Heron and found 13 differences, 3 worth asking the sponsor about: 7 bankruptcy cases name the subject or team members; 25% of the money raised went to insiders; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Patrick Heron has not run yet — it is joining a line of 22,009 names; searches run around the clock at the hosts' allowed rate. Searched so far: 378 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 3:01 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (checked Oct 24, 2026) · state securities regulators: VA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases + SEC administrative proceedings (sec.gov index, 1995-09-19 → 2026-10-23) — last checked Oct 24, 2026, 12:33 AM ET.

State securities regulators: Securities regulators searched (3,318 actions): AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE DOJ Investor Protection Unit (257 actions, 1987–2026), TX State Securities Board (586 actions, 2006–2026), WA DFI (2,039 actions, 2001–2026) — last crawled Oct 23, 2026, 9:57 PM ET. No machine-readable public listing today for CO, FL, IA, IN, MN, NE, NJ, NY, OH, UT, VA (see docs/state-regulators.md).

3. Bankruptcies

4 cases: 4 closed (disposition not in docket feed)

Patrick Heron closed
United States Bankruptcy Court, E.D. Michigan · No. 22-48803 · Filed Nov 9, 2022 · Closed Feb 16, 2023
Role of Patrick Heron: Debtor · Outcome: Case closed 2023-02-16 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 5 federal dockets); court in the person's filing state (MI)
Patrick J Heron closed
United States Bankruptcy Court, E.D. Michigan · No. 16-46822 · Filed May 4, 2016 · Closed Mar 20, 2018
Role of Patrick J Heron: Debtor · Outcome: Case closed 2018-03-20 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 5 federal dockets); court in the person's filing state (MI)
Patrick F. Heron, Jr. closed
United States Bankruptcy Court, E.D. Pennsylvania · No. 08-17299 · Filed Nov 4, 2008 · Closed Jan 15, 2009
Role of Patrick F. Heron, Jr.: Debtor · Outcome: Case closed 2009-01-15 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 5 federal dockets); court in the person's filing state (PA)
Patrick F. Heron closed
United States Bankruptcy Court, E.D. Pennsylvania · No. 00-19293 · Filed Jul 26, 2000 · Closed Apr 20, 2001
Role of Patrick F. Heron: Debtor · Outcome: Case closed 2001-04-20 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 5 federal dockets); court in the person's filing state (PA)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 3:01 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

13 differences found between the filings for Patrick Heron — 3 worth asking about (compared the newest 50 of 71 filings on Oct 24, 2026; older filings not covered)

Worth asking · Feb 8, 1991 – Feb 16, 2023

7 bankruptcy cases name the subject or team members

Bankruptcy case: Patrick Heron — filed Nov 9, 2022 · Bankruptcy case: Patrick J Heron — filed May 4, 2016 · Bankruptcy case: Patrick F. Heron, Jr. — filed Nov 4, 2008 · Bankruptcy case: Patrick F. Heron — filed Jul 26, 2000 · Bankruptcy case: American Express Centurion Bank v. Edick — filed Dec 19, 2014 · and 2 more

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, E.D. Michigan ↗Docket · United States Bankruptcy Court, E.D. Michigan ↗Docket · United States Bankruptcy Court, E.D. Pennsylvania ↗Docket · United States Bankruptcy Court, E.D. Pennsylvania ↗
Sources
Worth asking · Dec 11, 2014

25% of the money raised went to insiders — Imago BioSciences, Inc.

The Dec 11, 2014 Form D reports $8,833,330 sold and $2,242,956 of the proceeds used for payments to officers, directors or promoters.

What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.

Form D · Dec 11, 2014 ↗Imago BioSciences, Inc. — PartnerFacts page ↗
Sources
Worth asking · Jun 23, 2015 – Nov 18, 2022

Patrick Heron appears on 3 deals that stopped filing before reaching their target

MBX Biosciences, Inc. (last filing Nov 18, 2022; $46,675,441 sold of $115,184,430); Frazier Life Sciences X, L.P. (last filing Dec 17, 2019; $0 sold of $617,050,000); Nexcida Therapeutics, Inc. (last filing Jun 23, 2015; $2,750,002 sold of $21,250,003). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

MBX Biosciences, Inc. — PartnerFacts page ↗Frazier Life Sciences X, L.P. — PartnerFacts page ↗Nexcida Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Aug 27, 2013 – Sep 6, 2019

6 Form Ds were filed more than 15 days after the first sale

Form D filed 16 days after the first sale — Passage BIO, Inc. · Form D filed 18 days after the first sale — SutroVax, Inc. · Form D filed 42 days after the first sale — Imago BioSciences, Inc. · Form D filed 18 days after the first sale — Cidara Therapeutics, Inc. · Form D filed 18 days after the first sale — Cidara Therapeutics, Inc. · and 1 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Sep 6, 2019 ↗Passage BIO, Inc. — PartnerFacts page ↗Form D · Mar 21, 2017 ↗SutroVax, Inc. — PartnerFacts page ↗
Sources
Note · Jan 8, 2010 – Nov 18, 2022

17 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — MBX Biosciences, Inc. (latest filing Nov 18, 2022) · No amendment in the last 12 months on an offering that may still be open — Scout Bio, Inc. (latest filing Oct 15, 2021) · No amendment in the last 12 months on an offering that may still be open — Arcutis Biotherapeutics, Inc. (latest filing Oct 22, 2019) · No amendment in the last 12 months on an offering that may still be open — Passage BIO, Inc. (latest filing Sep 6, 2019) · No amendment in the last 12 months on an offering that may still be open — Imago BioSciences, Inc. (latest filing Mar 28, 2019) · and 12 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Nov 18, 2022 ↗MBX Biosciences, Inc. — PartnerFacts page ↗Form D · Oct 15, 2021 ↗Scout Bio, Inc. — PartnerFacts page ↗
Sources
Note · Mar 8, 2012 – Mar 2, 2018

6 offerings changed their target amount between filings

Offering amount changed between filings — Iterum Therapeutics plc · Offering amount changed between filings — Imago BioSciences, Inc. · Offering amount changed between filings — Iterum Therapeutics plc · Offering amount changed between filings — Frazier Healthcare Growth Buyout Fund VIII, L.P. · Offering amount changed between filings — Frazier Healthcare Growth Buyout Fund VIII, L.P. · and 1 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D (earlier) · Jun 1, 2017 ↗Form D/A (later) · Mar 2, 2018 ↗Iterum Therapeutics plc — PartnerFacts page ↗Form D (earlier) · Dec 11, 2014 ↗
Sources
Note · Oct 29, 2015 – Jan 12, 2016

Minimum investment changed between filings — Frazier Healthcare Growth Buyout Fund VIII, L.P.

The Oct 29, 2015 filing lists a minimum of $0; the Jan 12, 2016 Form D/A lists $75,000.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Oct 29, 2015 ↗Form D/A (later) · Jan 12, 2016 ↗Frazier Healthcare Growth Buyout Fund VIII, L.P. — PartnerFacts page ↗
Sources
Note · Jan 22, 2010 – Oct 29, 2015

Patrick Heron is written 2 different ways on the filings

listed as "Patrick Heron" on 31 filings (from Jan 22, 2010), and "Patrick J. Heron" on 21 filings (from Oct 29, 2015).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Jan 22, 2010 ↗Form D · Oct 29, 2015 ↗Patrick Heron — PartnerFacts page ↗
Sources
Note · Nov 20, 2018 – Jan 29, 2026

Industry group changed between filings — Mirum Pharmaceuticals, Inc.

"Pharmaceuticals" (Nov 20, 2018 to Dec 30, 2020); then "Biotechnology" (Jan 29, 2026).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Nov 20, 2018 ↗Form D · Jan 29, 2026 ↗Mirum Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Dec 2, 2015 – Jun 12, 2020

Industry group changed between filings — Iterum Therapeutics plc

"Biotechnology" (Dec 2, 2015 to Mar 2, 2018); then "Pharmaceuticals" (Jun 12, 2020 to Jul 7, 2020).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Dec 2, 2015 ↗Form D · Jun 12, 2020 ↗Iterum Therapeutics plc — PartnerFacts page ↗
Sources
Note · Nov 20, 2018 – Dec 30, 2020

Address moved from San Diego, CA to Foster City, CA — Mirum Pharmaceuticals, Inc.

The people listed on the Nov 20, 2018 filing give San Diego, CA; on the Dec 30, 2020 filing they give Foster City, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Nov 20, 2018 ↗Form D · Dec 30, 2020 ↗Mirum Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Jan 22, 2010 – Mar 8, 2012

Address moved from San Diego, CA to Seattle, WA — VentiRx Pharmaceuticals Inc.

The people listed on the Jan 22, 2010 filing give San Diego, CA; on the Mar 8, 2012 filing they give Seattle, WA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Jan 22, 2010 ↗Form D/A · Mar 8, 2012 ↗VentiRx Pharmaceuticals Inc. — PartnerFacts page ↗
Sources
Note · Jan 22, 2010 – Jun 30, 2026

Patrick Heron is listed with 7 different address states: WA, MA, CA, CO, L2, PA, IN

WA on 10 filings (Jan 22, 2010 to Dec 17, 2019); MA on 2 filings (Oct 2, 2013 to Mar 13, 2015); CA on 25 filings (Jun 17, 2014 to Jun 30, 2026); CO on 3 filings (Sep 12, 2014 to Oct 18, 2016); Ireland (as filed: L2) on 7 filings (Dec 2, 2015 to Jul 7, 2020); PA on 4 filings (Mar 13, 2018 to Oct 15, 2021); IN on 1 filing (Nov 18, 2022).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Jan 22, 2010 ↗Form D · Oct 2, 2013 ↗Form D · Jun 17, 2014 ↗Form D · Sep 12, 2014 ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. We compared the newest 50 of 71 filings (work cap); older filings are not covered here. As of Oct 24, 2026.

5. Money to insiders

3 of 59 offerings report sales commissions totalling $2,091,400; 0 report finder's fees; 1 reports proceeds to related persons totalling $2,242,956. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jun 30, 2026 D
Frazier Life Sciences Public Fund, L.P.
File 021-589142
$0 (est.)$0$0
The general partner is entitled to a performance allocation. The investment manager is entitled to a management fee. The performance allocation and management fee are fully discussed in the Issuer's confidential offering materials.
XT CAPITAL PARTNERS, LLC BrokerCheck CRD 118719 ↗EDGAR ↗
Jan 29, 2026 D
Mirum Pharmaceuticals, Inc.
File 021-571698
$0$0$0None listed on this filingEDGAR ↗
Mar 17, 2025 D
Frazier Life Sciences XII, L.P.
File 021-541158
$0$0$0None listed on this filingEDGAR ↗
Nov 18, 2022 D
MBX Biosciences, Inc.
File 021-465364
$0$0$0None listed on this filingEDGAR ↗
Mar 18, 2022 D
Frazier Life Sciences XI, L.P.
File 021-438073
$0$0$0None listed on this filingEDGAR ↗
Oct 15, 2021 D
Scout Bio, Inc.
File 021-417090
$0$0$0None listed on this filingEDGAR ↗
Dec 30, 2020 D
Mirum Pharmaceuticals, Inc.
File 021-384864
$0$0$0None listed on this filingEDGAR ↗
Nov 20, 2020 D
Imago BioSciences, Inc.
File 021-381115
$0$0$0None listed on this filingEDGAR ↗
Jul 7, 2020 D
Iterum Therapeutics plc
File 021-370375
$350,000$0$0H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗EDGAR ↗
Jun 12, 2020 D
Iterum Therapeutics plc
File 021-368874
$350,000$0$0H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗EDGAR ↗
Apr 3, 2020 D
SutroVax, Inc.
File 021-364301
$0$0$0None listed on this filingEDGAR ↗
Jan 31, 2020 D
Iterum Therapeutics Bermuda Ltd
File 021-359530
$1,391,400$0$0SVB Leerink LLC BrokerCheck CRD 39011 ↗EDGAR ↗
Dec 17, 2019 D
Frazier Life Sciences X, L.P.
File 021-355633
$0$0$0None listed on this filingEDGAR ↗
Oct 22, 2019 D
Arcutis Biotherapeutics, Inc.
File 021-351627
$0$0$0None listed on this filingEDGAR ↗
Sep 6, 2019 D
Passage BIO, Inc.
File 021-348117
$0$0$0None listed on this filingEDGAR ↗
Apr 11, 2019 D
Scout Bio, Inc.
File 021-337105
$0$0$0None listed on this filingEDGAR ↗
Mar 28, 2019 D
Imago BioSciences, Inc.
File 021-335883
$0$0$0N/A no CRD number reportedEDGAR ↗
Nov 20, 2018 D
Mirum Pharmaceuticals, Inc.
File 021-326260
$0$0$0None listed on this filingEDGAR ↗
Jul 12, 2018 D
Recida Therapeutics, Inc.
File 021-316724
$0$0$0None listed on this filingEDGAR ↗
Jun 12, 2018 D
SutroVax, Inc.
File 021-314375
$0$0$0None listed on this filingEDGAR ↗
Apr 10, 2018 D/A
Frazier Healthcare Growth Buyout Affiliates IX, L.P.
File 021-300817
$0$0$0None listed on this filingEDGAR ↗
Apr 9, 2018 D/A
Frazier Healthcare Growth Buyout Fund IX, L.P.
File 021-300820
$0$0$0None listed on this filingEDGAR ↗
Mar 13, 2018 D
Scout Bio, Inc.
File 021-307559
$0$0$0None listed on this filingEDGAR ↗
Mar 2, 2018 D/A
Iterum Therapeutics plc
File 021-287819
$0$0$0None listed on this filingEDGAR ↗
Nov 1, 2017 D
Frazier Life Sciences IX, L.P.
File 021-297918
$0$0$0
The General Partner receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the Issuer's limited partners (as set forth in the Issuer's partnership agreement).
None listed on this filingEDGAR ↗
Mar 21, 2017 D
SutroVax, Inc.
File 021-282968
$0$0$0None listed on this filingEDGAR ↗
Feb 22, 2017 D/A
Imago BioSciences, Inc.
File 021-229888
$0$0$2,242,956N/A no CRD number reportedEDGAR ↗
Dec 30, 2016 D/A
Iterum Therapeutics plc
File 021-252227
$0$0$0None listed on this filingEDGAR ↗
Oct 18, 2016 D
Silvergate Pharmaceuticals, Inc.
File 021-272793
$0$0$0None listed on this filingEDGAR ↗
Apr 4, 2016 D
Zavante Therapeutics, Inc.
File 021-260605
$0$0$0None listed on this filingEDGAR ↗
Mar 23, 2016 D/A
Frazier Healthcare Growth Buyout Fund VIII, L.P.
File 021-250280
$0$0$0
Frazier Management, L.L.C. receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the issuer's LPs.
None listed on this filingEDGAR ↗
Mar 23, 2016 D
Frazier Healthcare Growth Buyout Affiliates VIII, L.P.
File 021-259794
$0$0$0None listed on this filingEDGAR ↗
Oct 29, 2015 D
Frazier Life Sciences VIII, L.P.
File 021-250272
$0$0$0
The General Partner receives a fee for advisory services. The fee is generally a percentage of the aggregate subscriptions of the Issuer's limited partners (as set forth in the Issuer's partnership agreement).
None listed on this filingEDGAR ↗
Oct 14, 2015 D
Silvergate Pharmaceuticals, Inc.
File 021-249352
$0$0$0None listed on this filingEDGAR ↗
Jun 23, 2015 D
Nexcida Therapeutics, Inc.
File 021-242328
$0$0$0None listed on this filingEDGAR ↗
Mar 13, 2015 D
COLLEGIUM PHARMACEUTICAL, INC
File 021-235865
$0$0$0None listed on this filingEDGAR ↗
Feb 17, 2015 D
Cidara Therapeutics, Inc.
File 021-234129
$0$0$0None listed on this filingEDGAR ↗
Sep 30, 2014 D
VentiRx Pharmaceuticals Inc.
File 021-225512
$0 (est.)$0 (est.)$0 (est.)None listed on this filingEDGAR ↗
Sep 23, 2014 D/A
VentiRx Pharmaceuticals Inc.
File 021-91597
$0 (est.)$0 (est.)$0 (est.)None listed on this filingEDGAR ↗
Sep 12, 2014 D
Silvergate Pharmaceuticals, Inc.
File 021-224578
$0$0$0None listed on this filingEDGAR ↗
Jun 17, 2014 D
Cidara Therapeutics, Inc.
File 021-219307
$0$0$0None listed on this filingEDGAR ↗
Jun 17, 2014 D
Cidara Therapeutics, Inc.
File 021-219340
$0$0$0None listed on this filingEDGAR ↗
Oct 2, 2013 D
COLLEGIUM PHARMACEUTICAL, INC
File 021-203887
$0$0$0None listed on this filingEDGAR ↗
Sep 30, 2013 D/A
Frazier Healthcare VII, L.P.
File 021-180706
$0$0$0 (est.)
An affiliate of the General Partner will receive an investment advisory fee payable by the Issuer quarterly in advance. The investment advisory fee will generally be equal to a percentage of commitments as specified in the Issuer's constituent agreement.
None listed on this filingEDGAR ↗
Jun 14, 2013 D/A
Silvergate Pharmaceuticals, Inc.
File 021-159955
$0$0$0None listed on this filingEDGAR ↗
May 8, 2013 D
Frazier Healthcare VII-A, L.P.
File 021-196141
$0$0$0 (est.)
The general partner or an affiliate thereof will receive a management fee payable by FH VII.
None listed on this filingEDGAR ↗
Nov 13, 2012 D/A
Precision Dermatology, Inc.
File 021-177698
$0$0$0None listed on this filingEDGAR ↗
Feb 24, 2012 D
COLLEGIUM PHARMACEUTICAL, INC
File 021-173910
$0$0$0None listed on this filingEDGAR ↗
Mar 16, 2011 D
Informed Medical Communications, Inc.
File 021-156800
$0$0$0None listed on this filingEDGAR ↗
Mar 11, 2011 D
Informed Medical Communications, Inc.
File 021-156607
$0$0$0None listed on this filingEDGAR ↗
Mar 9, 2011 D
KALIDEX PHARMACEUTICALS, INC.
File 021-156449
$0 (est.)$0 (est.)$0 (est.)None listed on this filingEDGAR ↗
Nov 24, 2010 D
Precision Dermatology, Inc.
File 021-151020
$0$0$0None listed on this filingEDGAR ↗
Nov 10, 2010 D
KALIDEX PHARMACEUTICALS, INC.
File 021-150283
$0 (est.)$0 (est.)$0 (est.)None listed on this filingEDGAR ↗
Aug 30, 2010 D
Tobira Therapeutics, Inc.
File 021-147084
$0$0$0None listed on this filingEDGAR ↗
Jul 14, 2010 D
Tobira Therapeutics, Inc.
File 021-144909
$0$0$0None listed on this filingEDGAR ↗
Mar 11, 2010 D
Tobira Therapeutics, Inc.
File 021-107416
$0$0$0None listed on this filingEDGAR ↗
Mar 8, 2010 D
COLLEGIUM PHARMACEUTICAL, INC
File 021-59559
$0$0$0None listed on this filingEDGAR ↗
Sep 4, 2009 D
Trubion Pharmaceuticals, Inc
File 021-67751
$0$0$0None listed on this filingEDGAR ↗
Apr 24, 2009 D
QUATRX PHARMACEUTICALS Co
File 021-39151
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 34

Every issuer that named Patrick Heron on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

FL
Pooled Investment Fund

Frazier Life Sciences Public Fund, L.P.

Palo Alto, CA · Jun 30, 2026
  • Jun 30, 2026 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer, Promoter (Managing Member of the GP of the GP of the Issuer) EDGAR ↗

Raised $475.7M from 142 investors as of the latest filing. Patrick is listed as executive officer, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MP
Biotechnology

Mirum Pharmaceuticals, Inc.

Foster City, CA · Nov 20, 2018 → Jan 29, 2026 · 3 filings
  • Jan 29, 2026 · D · $68,480,000 sold of $68,480,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 30, 2020 · D · $10,000,000 sold of $10,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 20, 2018 · D · $60,063,750 sold of $120,063,750 · 14 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $68.5M from 14 investors (100% of the $68.5M target) as of the latest filing. Patrick is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(c) (163 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FL
Pooled Investment Fund

Frazier Life Sciences XII, L.P.

Palo Alto, CA · Mar 17, 2025
  • Mar 17, 2025 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Executive Officer (Member of the General Partner of the General Partner) EDGAR ↗

No sales reported yet as of the latest filing. Patrick is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MB
Pharmaceuticals

MBX Biosciences, Inc.

Carmel, IN · Nov 18, 2022
  • Nov 18, 2022 · D · $46,675,441 sold of $115,184,430 · 20 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $46.7M from 20 investors (41% of the $115.2M target) as of the latest filing. Patrick is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FL
Pooled Investment Fund

Frazier Life Sciences XI, L.P.

Menlo Park, CA · Mar 18, 2022
  • Mar 18, 2022 · D · $960,000,000 sold of $960,000,000 · 98 investors · min. No minimum reported · role: Executive Officer (Member of the General Partner of the General Partner) EDGAR ↗

Raised $960M from 98 investors (100% of the $960M target) as of the latest filing. Patrick is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SB
Other

Scout Bio, Inc.

Philadelphia, PA · Mar 13, 2018 → Oct 15, 2021 · 3 filings
  • Oct 15, 2021 · D · $4,750,005 sold of $12,999,993 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 11, 2019 · D · $20,000,004 sold of $20,000,004 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 13, 2018 · D · $9,290,416 sold of $9,290,416 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $20M from 6 investors (100% of the $13M target) as of the latest filing. Patrick is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

IB
Other Health Care

Imago BioSciences, Inc.

San Carlos, CA · Dec 11, 2014 → Nov 20, 2020 · 4 filings
  • Nov 20, 2020 · D · $79,999,992 sold of $79,999,992 · 28 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 28, 2019 · D · $16,999,998 sold of $39,999,994 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 22, 2017 · D/A · $40,499,995 sold of $40,499,995 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 11, 2014 · D · $8,833,330 sold of $26,499,997 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $80M from 28 investors (100% of the $80M target) as of the latest filing. Patrick is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

IT
Pharmaceuticals · group: Iterum Therapeutics

Iterum Therapeutics plc

Dublin, Ireland (as filed: L2) · Dec 2, 2015 → Jul 7, 2020 · 6 filings
  • Jul 7, 2020 · D · $2,832,102 sold of $2,832,102 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 12, 2020 · D · $2,844,627 sold of $2,844,627 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 2, 2018 · D/A · $78,097,985 sold of $78,097,985 · 17 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 1, 2017 · D · $45,867,493 sold of $65,524,992 · 17 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 30, 2016 · D/A · $47,639,999 sold of $47,640,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 2, 2015 · D · $23,790,001 sold of $47,490,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $78.1M from 17 investors (100% of the $2.83M target) as of the latest filing. Patrick is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

S
Biotechnology

SutroVax, Inc.

Foster City, CA · Mar 21, 2017 → Apr 3, 2020 · 3 filings
  • Apr 3, 2020 · D · $110,000,000 sold of $110,000,000 · 23 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 12, 2018 · D · $43,182,959 sold of $85,682,959 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 21, 2017 · D · $40,100,007 sold of $60,150,027 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $110M from 23 investors (100% of the $110M target) as of the latest filing. Patrick is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

IT
Pharmaceuticals · group: Iterum Therapeutics

Iterum Therapeutics Bermuda Ltd

Hamilton, Bermuda (as filed: D0) · Jan 31, 2020
  • Jan 31, 2020 · D · $51,588,000 sold of $51,588,000 · 31 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $51.6M from 31 investors (100% of the $51.6M target) as of the latest filing. Patrick is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FL
Pooled Investment Fund

Frazier Life Sciences X, L.P.

Seattle, WA · Dec 17, 2019
  • Dec 17, 2019 · D · $0 sold of $617,050,000 · 0 investors · min. No minimum reported · role: Executive Officer (Member of the General Partner of the General Partner) EDGAR ↗

No sales reported yet as of the latest filing. Patrick is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AB
Biotechnology

Arcutis Biotherapeutics, Inc.

Westlake Village, CA · Oct 22, 2019
  • Oct 22, 2019 · D · $94,499,967 sold of $94,500,000 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $94.5M from 16 investors (100% of the $94.5M target) as of the latest filing. Patrick is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

PB
Other Health Care

Passage BIO, Inc.

Philadelphia, PA · Sep 6, 2019
  • Sep 6, 2019 · D · $109,999,974 sold of $110,000,000 · 15 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $110M from 15 investors (100% of the $110M target) as of the latest filing. Patrick is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RT
Biotechnology

Recida Therapeutics, Inc.

Menlo Park, CA · Jul 12, 2018
  • Jul 12, 2018 · D · $5,667,877 sold of $10,667,877 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $5.67M from 1 investor (53% of the $10.7M target) as of the latest filing. Patrick is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare Growth Buyout Affiliates IX, L.P.

Seattle, WA · Dec 14, 2017 → Apr 10, 2018 · 2 filings
  • Apr 10, 2018 · D/A · $6,440,000 sold of Indefinite · 33 investors · min. No minimum reported · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗
  • Dec 14, 2017 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗

Raised $6.44M from 33 investors as of the latest filing. Patrick is listed as promoter on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare Growth Buyout Fund IX, L.P.

Seattle, WA · Dec 14, 2017 → Apr 9, 2018 · 2 filings
  • Apr 9, 2018 · D/A · $775,712,511 sold of Indefinite · 138 investors · min. No minimum reported · role: Promoter (Member of the Issuers' affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗
  • Dec 14, 2017 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Promoter (Member of the Issuers' affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗

Raised $775.7M from 138 investors as of the latest filing. Patrick is listed as promoter on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FL
Pooled Investment Fund · group: Frazier Healthcare

Frazier Life Sciences IX, L.P.

Seattle, WA · Nov 1, 2017
  • Nov 1, 2017 · D · $418,925,000 sold of $418,925,000 · 55 investors · min. No minimum reported · role: Executive Officer (Member of the general partner of the Issuer's general partner) EDGAR ↗

Raised $418.9M from 55 investors (100% of the $418.9M target) as of the latest filing. Patrick is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SP
Pharmaceuticals

Silvergate Pharmaceuticals, Inc.

Greenwood Village, CO · May 17, 2011 → Oct 18, 2016 · 5 filings
  • Oct 18, 2016 · D · $4,600,000 sold of $4,600,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 14, 2015 · D · $1,600,000 sold of $4,600,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 12, 2014 · D · $1,000,000 sold of $1,000,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 14, 2013 · D/A · $23,554,167 sold of $23,554,167 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 17, 2011 · D · $3,015,000 sold of $3,015,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $23.6M from 13 investors (100% of the $4.6M target) as of the latest filing. Patrick is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ZT
Pharmaceuticals

Zavante Therapeutics, Inc.

San Diego, CA · Apr 4, 2016
  • Apr 4, 2016 · D · $45,731,764 sold of $45,731,764 · 54 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $45.7M from 54 investors (100% of the $45.7M target) as of the latest filing. Patrick is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare Growth Buyout Affiliates VIII, L.P.

Seattle, WA · Mar 23, 2016
  • Mar 23, 2016 · D · $5,000,000 sold of $5,000,000 · 21 investors · min. $100,000 · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗

Raised $5M from 21 investors (100% of the $5M target) as of the latest filing. Patrick is listed as promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare Growth Buyout Fund VIII, L.P.

Seattle, WA · Oct 29, 2015 → Mar 23, 2016 · 3 filings
  • Mar 23, 2016 · D/A · $519,612,246 sold of $519,612,246 · 67 investors · min. $75,000 · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗
  • Jan 12, 2016 · D/A · $435,000,000 sold of $500,000,000 · 62 investors · min. $75,000 · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗
  • Oct 29, 2015 · D · $0 sold of Indefinite · 0 investors · min. No minimum reported · role: Promoter (Member of the Issuer's affiliated advisor, Frazier Management, L.L.C.) EDGAR ↗

Raised $519.6M from 67 investors (100% of the $519.6M target) as of the latest filing. Patrick is listed as promoter on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FL
Pooled Investment Fund · group: Frazier Healthcare

Frazier Life Sciences VIII, L.P.

Seattle, WA · Oct 29, 2015
  • Oct 29, 2015 · D · $262,000,000 sold of $262,000,000 · 46 investors · min. $68,750 · role: Executive Officer (Member of the general partner of the Issuer's general partner) EDGAR ↗

Raised $262M from 46 investors (100% of the $262M target) as of the latest filing. Patrick is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

NT
Other

Nexcida Therapeutics, Inc.

Menlo Park, CA · Jun 23, 2015
  • Jun 23, 2015 · D · $2,750,002 sold of $21,250,003 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $2.75M from 5 investors (13% of the $21.3M target) as of the latest filing. Patrick is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

CP
Pharmaceuticals

COLLEGIUM PHARMACEUTICAL, INC

Stoughton, MA · Mar 8, 2010 → Mar 13, 2015 · 4 filings
  • Mar 13, 2015 · D · $50,000,000 sold of $50,000,000 · 18 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 2, 2013 · D · $4,000,002 sold of $12,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 24, 2012 · D · $22,461,190 sold of $22,461,190 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 8, 2010 · D · $1,000,000 sold of $2,500,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $50M from 18 investors (100% of the $50M target) as of the latest filing. Patrick is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

CT
Biotechnology · group: Trius

Cidara Therapeutics, Inc.

San Diego, CA · Jun 17, 2014 → Feb 17, 2015 · 3 filings
  • Feb 17, 2015 · D · $42,019,999 sold of $42,019,999 · 19 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 17, 2014 · D · $30,332,199 sold of $42,743,763 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 17, 2014 · D · $6,000,472 sold of $6,000,472 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $240M from 19 investors (100% of the $42M target) as of the latest filing. Patrick is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VP
Biotechnology

VentiRx Pharmaceuticals Inc.

Seattle, WA · Jan 22, 2010 → Sep 30, 2014 · 4 filings
  • Sep 30, 2014 · D · $15,000,000 sold of $15,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 23, 2014 · D/A · $50,602,514 sold of $53,102,414 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 8, 2012 · D/A · $18,750,001 sold of $25,000,002 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 22, 2010 · D · $12,500,001 sold of $25,000,002 · 5 investors · min. $1 · role: Director EDGAR ↗

Raised $50.6M from 9 investors (100% of the $15M target) as of the latest filing. Patrick is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare VII, L.P.

Seattle, WA · Jul 3, 2012 → Sep 30, 2013 · 2 filings
  • Sep 30, 2013 · D/A · $293,943,299 sold of $400,000,000 · 37 investors · min. $50,000 · role: Executive Officer (Member of the general partner of the Issuer's general partner) EDGAR ↗
  • Jul 3, 2012 · D · $0 sold of $400,000,000 · 0 investors · min. $1,000,000 · role: Executive Officer (Member of the general partner of the Issuer's general partner) EDGAR ↗

Raised $293.9M from 37 investors (73% of the $400M target) as of the latest filing. Patrick is listed as executive officer on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FH
Pooled Investment Fund · group: Frazier Healthcare

Frazier Healthcare VII-A, L.P.

Seattle, WA · May 8, 2013
  • May 8, 2013 · D · $82,500,000 sold of $82,500,000 · 3 investors · min. $1,000,000 · role: Executive Officer (Member of the general partner of the Issuer's general partner) EDGAR ↗

Raised $82.5M from 3 investors (100% of the $82.5M target) as of the latest filing. Patrick is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

PD
Other Health Care

Precision Dermatology, Inc.

Cumberland, RI · Nov 24, 2010 → Nov 13, 2012 · 3 filings
  • Nov 13, 2012 · D/A · $55,000,001 sold of $58,100,001 · 0 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 4, 2012 · D · $29,400,001 sold of $40,000,000 · 0 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 24, 2010 · D · $19,000,001 sold of $20,000,001 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $55M from 10 investors (95% of the $58.1M target) as of the latest filing. Patrick is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

IM
Other Health Care

Informed Medical Communications, Inc.

Edison, NJ · Mar 11, 2011 → Mar 16, 2011 · 2 filings
  • Mar 16, 2011 · D · $7,628,078 sold of $7,628,078 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 11, 2011 · D · $7,246,674 sold of $7,246,674 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $7.63M from 6 investors (100% of the $7.63M target) as of the latest filing. Patrick is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

KP
Pharmaceuticals

KALIDEX PHARMACEUTICALS, INC.

Menlo Park, CA · Nov 10, 2010 → Mar 9, 2011 · 2 filings
  • Mar 9, 2011 · D · $8,249,998 sold of $44,999,989 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 10, 2010 · D · $250,628 sold of $500,628 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $8.25M from 8 investors (18% of the $45M target) as of the latest filing. Patrick is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

TT
Biotechnology

Tobira Therapeutics, Inc.

Manalapan, NJ · Mar 11, 2010 → Aug 30, 2010 · 3 filings
  • Aug 30, 2010 · D · $14,199,776 sold of $31,199,776 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 14, 2010 · D · $4,999,999 sold of $10,999,999 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 11, 2010 · D · $4,000,000 sold of $4,000,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $14.2M from 6 investors (46% of the $31.2M target) as of the latest filing. Patrick is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

TP
Biotechnology

Trubion Pharmaceuticals, Inc

Seattle, WA · Sep 4, 2009
  • Sep 4, 2009 · D · $10,000,000 sold of $10,000,000 · 1 investors · min. $10,000,000 · role: Director EDGAR ↗

Raised $10M from 1 investor (100% of the $10M target) as of the latest filing. Patrick is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

QP
Pharmaceuticals

QUATRX PHARMACEUTICALS Co

Ann Arbor, MI · Apr 24, 2009
  • Apr 24, 2009 · D · $14,025,045 sold of $37,055,718 · 17 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $14M from 17 investors (38% of the $37.1M target) as of the latest filing. Patrick is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

People around Patrick 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

FM
Management entity

Frazier Management, L.L.C.

Promoter · 9 shared filings (5 issuers)

Frazier Management, L.L.C. is on 5 issuers in total — a repeat sponsor. Their page lists every one.

FG
Management entity

FHM Growth Buyout VIII, L.L.C.

Executive Officer · 4 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

FG
Management entity

FHM Growth Buyout IX, L.L.C.

Executive Officer · 4 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

FV
Management entity

FHM VII, L.L.C.

Executive Officer · 3 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

DF
Management entity

D. Frazier Management, L.L.C.

Promoter · 1 shared filing (1 issuer)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

FL
Management entity

FHM Life Sciences VIII, L.L.C.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

FI
Management entity

FHMLS IX, L.L.C.

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

NE
No photo found yet (own website and image search run after this page is viewed)
Person

Nathan Every

Director, Executive Officer, Promoter · 17 shared filings (8 issuers) · also on 21 other issuers

Nathan Every is on 29 issuers in total — a repeat sponsor. Their page lists every one.

JT
No photo found yet (own website and image search run after this page is viewed)
Person

James Topper

Executive Officer, Promoter · 16 shared filings (11 issuers) · also on 13 other issuers

James Topper is on 24 issuers in total — a repeat sponsor. Their page lists every one.

NN
No photo found yet (own website and image search run after this page is viewed)
Person

Nader Naini

Executive Officer, Promoter · 12 shared filings (7 issuers) · also on 22 other issuers

Nader Naini is on 29 issuers in total — a repeat sponsor. Their page lists every one.

AF
No photo found yet (own website and image search run after this page is viewed)
Person

Alan Frazier

Executive Officer, Promoter · 12 shared filings (7 issuers) · also on 5 other issuers

Alan Frazier is on 12 issuers in total — a repeat sponsor. Their page lists every one.

BM
No photo found yet (own website and image search run after this page is viewed)
Person

BRIAN MORFITT

Director, Executive Officer · 10 shared filings (5 issuers) · also on 14 other issuers

BRIAN MORFITT is on 19 issuers in total — a repeat sponsor. Their page lists every one.

BM
No photo found yet (own website and image search run after this page is viewed)
Person

Ben Magnano

Executive Officer · 7 shared filings (4 issuers) · also on 16 other issuers

Ben Magnano is on 20 issuers in total — a repeat sponsor. Their page lists every one.

CF
No photo found yet (own website and image search run after this page is viewed)
Person

Corey N. Fishman

Executive Officer, Director, Promoter · 7 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

MD
No photo found yet (own website and image search run after this page is viewed)
Person

Michael W. Dunne

Executive Officer, Promoter · 7 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

Judith M. Matthews

Executive Officer, Promoter · 7 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

BA
No photo found yet (own website and image search run after this page is viewed)
Person

Brenton K. Ahrens

Director · 7 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

RH
No photo found yet (own website and image search run after this page is viewed)
Person

Ronald M. Hunt

Director · 7 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Patrick Heron. Their page shows their other deals.

MH
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Heffernan

Executive Officer, Director · 7 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as Patrick Heron. Their page shows their other deals.

PE
No photo found yet (own website and image search run after this page is viewed)
Person

Paul R. Edick

Director · 6 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

DK
No photo found yet (own website and image search run after this page is viewed)
Person

David I. Kelly

Director · 6 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

JH
No photo found yet (own website and image search run after this page is viewed)
Person

James Healy

Director · 5 shared filings (2 issuers) · also on 16 other issuers

James Healy is on 18 issuers in total — a repeat sponsor. Their page lists every one.

MP
No photo found yet (own website and image search run after this page is viewed)
Person

Mark Parrish

Director, Executive Officer · 5 shared filings (1 issuer)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

FS
No photo found yet (own website and image search run after this page is viewed)
Person

Frank Segrave

Executive Officer, Director, Promoter · 5 shared filings (1 issuer)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

MC
No photo found yet (own website and image search run after this page is viewed)
Person

Mark Chin

Director · 5 shared filings (2 issuers) · also on 3 other issuers

Mark Chin is on 5 issuers in total — a repeat sponsor. Their page lists every one.

SM
No photo found yet (own website and image search run after this page is viewed)
Person

Shahzad Malik

Director · 5 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

LF
No photo found yet (own website and image search run after this page is viewed)
Person

Laurent Fischer

Director · 5 shared filings (2 issuers) · also on 2 other issuers

Listed on the same filings as Patrick Heron. Their page shows their other deals.

DH
No photo found yet (own website and image search run after this page is viewed)
Person

Dennis Henner

Director · 4 shared filings (1 issuer) · also on 5 other issuers

Dennis Henner is on 6 issuers in total — a repeat sponsor. Their page lists every one.

HR
No photo found yet (own website and image search run after this page is viewed)
Person

Hugh Y. Rienhoff, Jr.

Executive Officer, Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Patrick Heron. Their page shows their other deals.

ST
No photo found yet (own website and image search run after this page is viewed)
Person

Steven N. Tannenbaum

Executive Officer · 4 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

PF
No photo found yet (own website and image search run after this page is viewed)
Person

Patrick Fortune

Director · 4 shared filings (2 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

RD
No photo found yet (own website and image search run after this page is viewed)
Person

Robert M. Hershberg, M.D., Ph.D.

Executive Officer, Director · 4 shared filings (1 issuer)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

MK
No photo found yet (own website and image search run after this page is viewed)
Person

Michael J. Kamdar

Director, Executive Officer · 4 shared filings (2 issuers) · also on 2 other issuers

Listed on the same filings as Patrick Heron. Their page shows their other deals.

SD
No photo found yet (own website and image search run after this page is viewed)
Person

Steven Gillis, Ph.D.

Director · 4 shared filings (1 issuer)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

YG
No photo found yet (own website and image search run after this page is viewed)
Person

Yigong (James) Ge

Executive Officer, Director · 4 shared filings (3 issuers)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

DH
No photo found yet (own website and image search run after this page is viewed)
Person

David Hirsch

Director · 4 shared filings (2 issuers) · also on 22 other issuers

David Hirsch is on 24 issuers in total — a repeat sponsor. Their page lists every one.

KS
No photo found yet (own website and image search run after this page is viewed)
Person

Kent Snyder

Director · 4 shared filings (1 issuer)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

RM
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Mauro

Executive Officer, Promoter · 4 shared filings (1 issuer)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

LE
No photo found yet (own website and image search run after this page is viewed)
Person

Laura G. Eichorn

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as Patrick Heron. Their page shows their other deals.

NV
No photo found yet (own website and image search run after this page is viewed)
Person

Nicole Vitullo

Director · 4 shared filings (1 issuer) · also on 8 other issuers

Nicole Vitullo is on 9 issuers in total — a repeat sponsor. Their page lists every one.

The team behind the deals

FH
Sponsor group

Frazier Healthcare

26 issuers · 34 filings · $2.74B reported sold · 2012–2026

One team, 26 deal companies. Patrick Heron is listed on 8 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Patrick Heron.

IT
Sponsor group

Iterum Therapeutics

2 issuers · 7 filings · $54.4M reported sold · 2015–2020

One team, 2 deal companies. Patrick Heron is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Patrick Heron.

T
Sponsor group

Trius

2 issuers · 9 filings · $270.2M reported sold · 2009–2024

One team, 2 deal companies. Patrick Heron is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Patrick Heron.

Same business address

51 other issuers file from the same address (first 50 shown)

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

A person is never an adviser firm. 5 of the 34 issuers this person is listed on match a Form ADV adviser (searched 24,962 advisers as of Oct 2, 2026): Frazier Healthcare Growth Buyout Affiliates IX, L.P., Frazier Healthcare Growth Buyout Fund IX, L.P., Frazier Life Sciences IX, L.P., Frazier Healthcare Growth Buyout Fund VIII, L.P., Frazier Healthcare Growth Buyout Affiliates VIII, L.P..

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Patrick Heron by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 34 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Patrick Heron is listed on: none on file. No website or social profile named in Frazier Life Sciences XI, L.P.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #161,812 of 374,652 in line (701 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Menlo Park, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗New Jersey state courts — find the court ↗Rhode Island state courts — find the court ↗Washington Courts case search (dw.courts.wa.gov) ↗Franklin County OH Clerk of Courts ↗Colorado state courts — find the court ↗Massachusetts MassCourts ↗Pennsylvania UJS portal case search ↗Indiana state courts — find the court ↗Michigan state courts — find the court ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗New Jersey Secretary of State business search ↗Rhode Island Secretary of State business search ↗Washington Secretary of State business search ↗Ohio Secretary of State business search ↗Colorado Secretary of State business search ↗Massachusetts Secretary of State business search ↗Pennsylvania Secretary of State business search ↗Indiana Secretary of State business search ↗Michigan Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Patrick Heron appears on a new Form D, or when a court case or SEC action is matched to them. See plans →